会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 선택적 FXa 억제활성을 갖는 알라닌 유도체
    • 具有选择性FXA抑制活性的ALANINE衍生物
    • KR1020010081600A
    • 2001-08-29
    • KR1020000007489
    • 2000-02-17
    • 주식회사 엘지
    • 박태교장혜경이태희문광율이상구윤경희권오환강명균박두희이선화이승학김은경황광연허용석
    • C07D417/14
    • PURPOSE: The alanine derivatives having selective FXa inhibiting activity are provided, which show the improved selectivity to similar enzymes such as trypsin and thrombin, and is thus used for the prevention and treatment of thrombosis. CONSTITUTION: The alanine derivatives are represented by formula, in which D is selected from NH2, CN, aminoiminomethyl and aminomethyl; A is phenyl, hydroxyphenyl, pyridine, pyrol, furan, thiophene, oxazole, isooxazole, imidazole, 1,2-diazole, thiazole, isothiazole, pyridazine, pyrimidine, pyrazine, naphthalene, quinoline, isoquinoline, benzofuran, benzothiophene and indole; Y is selected from CO2R, CH2OR, CH2OAr, wherein Ar is phenyl, pyridine, pyrol, furan, thiophene, oxazole, isooxazole, imidazole, 1,2-diazole, thiazole, isothiazole, pyridazine, pyrimidine, pyrazine, 1,2,3-triazole, 1,2,4-triazole, tetrazol or 1,35-triazine, CH2O(C=O)R, CH2O(C=O)Ar, CONR(R1) and CON(R1)2 when X is NRCO, wherein R is hydrogen or linear, branched, ring, or partial ring lower alkyl having carbon number of 10 or less, NRSO2; P and Q are individually selected from phenyl, pyridine, pyrol, furan, thiopen, oxazole, isooxazole, imidazole, 1,2-diazole, thiazole, isothiazole, pyridazine, pyrimidine, pyrazine, 1,2,3-triazole, 1,2,4-triazole, tetrazol and 1,3,5-triazine; and G1, G2 and G3 are individually selected from H, F, Cl, Br, I, CN, R, OR, SR, NR2, CO2R, COR, CONR2, NR(=O)R, NR(C=O)Ar, N((C=O)R)2, SO2R, SO2NR2, S(=O)R, C(=NH)NH2, CF3, OCF3, SCF3 and NR(C=O)CF3.
    • 目的:提供具有选择性FXa抑制活性的丙氨酸衍生物,其表现出对类似酶如胰蛋白酶和凝血酶的改善的选择性,因此用于预防和治疗血栓形成。 构成:丙氨酸衍生物由式表示,其中D选自NH 2,CN,氨基亚氨基甲基和氨基甲基; A是苯基,羟基苯基,吡啶,吡咯,呋喃,噻吩,恶唑,异恶唑,咪唑,1,2-二唑,噻唑,异噻唑,哒嗪,嘧啶,吡嗪,萘,喹啉,异喹啉,苯并呋喃,苯并噻吩和吲哚; Y选自CO2R,CH2OR,CH2OAr,其中Ar是苯基,吡啶,吡咯,呋喃,噻吩,恶唑,异恶唑,咪唑,1,2-二唑,噻唑,异噻唑,哒嗪,嘧啶,吡嗪,1,2,3 当X为NRCO时,三唑,1,2,4-三唑,四唑或1,3,5-三嗪CH 2 O(C = O)R,CH 2 O(C = O)Ar,CONR(R 1)和CON(R 1) 其中R是氢或碳数为10以下的直链,支链,环或部分环低级烷基,NRSO 2; P和Q分别选自苯基,吡啶,吡咯,呋喃,噻吩,恶唑,异恶唑,咪唑,1,2-二唑,噻唑,异噻唑,哒嗪,嘧啶,吡嗪,1,2,3-三唑,1,2 ,4-三唑,四唑和1,3,5-三嗪; 并且G1,G2和G3分别选自H,F,Cl,Br,I,CN,R,OR,SR,NR2,CO2R,COR,CONR2,NR(= O)R,NR(C = O)Ar ,N((C = O)R)2,SO 2 R,SO 2 NR 2,S(= O)R,C(= NH)NH 2,CF 3,OCF 3,SCF 3和NR(C = O)CF 3。
    • 2. 发明授权
    • 신규 세팔로스포린계 항생제 및 이의 제조방법
    • 新西酞菁抗生素
    • KR100257130B1
    • 2000-05-15
    • KR1019930018321
    • 1993-09-11
    • 주식회사 엘지
    • 여재홍방찬식임종찬우영민양덕호김세호전재훈김무용김삼식이태희김용주오헌승
    • C07D501/24
    • C07D501/00Y02P20/55
    • PURPOSE: A novel cephalosporin antibiotic product comprising the cephalosporin compound and other acceptable salts is provided for accomplishing excellent antibiotic activity to wide ranges of pathogenic bacteria including gram negative bacilli producing beta-lactamase and improved pharmaco-dynamic property. CONSTITUTION: The cephalosporin antibiotic product useful as antibiotic agent to pathogenic bacteria and having high pharmacological dynamic property comprises the cephalosporin compound of formula I (wherein R1 is hydrogen or amino protecting group; R2 and R3 are same or different and each represent hydrogen or hydroxy protecting groups or together form cyclic diol protecting group; R4 is hydrogen or carboxyl protecting group; R5, R6 and R7 are independently hydrogen, amino group or substituted amino, hydroxy or alkoxy group, C1-C4 alkyl group, carboxy or alkoxy carbonyl group, provided that R6 and R7 should form C3-C7 rings together with carbon atoms bonded to them; and Q is CH or N) and pharmaceutical acceptable and non-toxic salts, physiologically hydrolytic ester, hydrate and solvent and isomers thereof.
    • 目的:提供一种包含头孢菌素化合物和其他可接受的盐的新型头孢菌素抗生素产品,用于对广泛范围的致病菌(包括革兰氏阴性杆菌产生β-内酰胺酶)和改善的药物 - 动力学性能实现优异的抗生素活性。 构成:用作致病菌抗菌素并且具有高药理动力学性质的头孢菌素抗生素产品包括式I的头孢菌素化合物(其中R 1为氢或氨基保护基; R 2和R 3相同或不同,各自表示氢或羟基保护基 基团或一起形成环状二醇保护基; R4是氢或羧基保护基; R5,R6和R7独立地是氢,氨基或取代的氨基,羟基或烷氧基,C1-C4烷基,羧基或烷氧基羰基, R6和R7应与其键合的碳原子一起形成C 3 -C 7环; Q是CH或N)和药学上可接受的和无毒的盐,生理水解酯,水合物和溶剂及其异构体。
    • 3. 发明授权
    • 신규 세팔로스포린계 항생제 및 이의 제조방법
    • 新CEPHOROSPORIN抗生素及其制备方法
    • KR100126619B1
    • 1998-04-01
    • KR1019940019957
    • 1994-08-12
    • 주식회사 엘지
    • 임종찬김용주여재홍방찬식우영민문영춘전재훈김삼식이태희김무용오헌승
    • C07D501/46
    • Y02P20/55
    • Cephalosporin compounds(I) having (Z)-2(2-aminothiazol-4-yl)-2-(alpa-carboxy-3,4-substituted benzyl oxyimino)acetamide group on 7-betaposition and 4-amino pyrimidinium methyl group on C-3 position exhibit a strong anti-microbial activity and a broad antibacterial spectrum. Title compounds(I) are prepared by the reaction of compound(II) and compound(III) in organic solvent such as lower alkylnitrile, lower halogenized alkane, tetrahydrofuran, or dioxane at 20-40 deg.C, where amino-protecting group or acid-protecting group, if necessary, is eliminated and S-oxide is reduced to give the title compounds. In formula, R1 is H or amino-protecting group; R2 and R3 can be identical or different and each represents H or hydroxy-protecting group or R2 and R3 can form a cyclic diol-protecting group; R4 is H or carboxyl-protecting group; R5 is negative charge or carboxyl-protecting group; R6 or R7 is H, C1-4 alkyl, (substituted) amino, or hydroxy group; R8 is H, C1-4 alkyl, amino or hydroxy group; Q is -CH- or =N-; X is leaving group; and m is 0 or 1.
    • 在7-位和4-氨基嘧啶甲基上具有(Z)-2(2-氨基噻唑-4-基)-2-(α-羧基-3,4-取代的苄基亚氨基)乙酰胺基团的头孢菌素化合物(I) C-3位具有很强的抗微生物活性和广泛的抗菌谱。 标题化合物(I)通过化合物(II)和化合物(III)在有机溶剂如低级烷基腈,低级卤代烷烃,四氢呋喃或二恶烷中在20-40℃反应制备,其中氨基保护基或 如果需要,除去酸保护基,还原S-氧化物,得到标题化合物。 在式中,R 1为H或氨基保护基; R2和R3可以相同或不同,各自表示H或羟基保护基,R2和R3可以形成环状二醇保护基; R4是H或羧基保护基; R5是负电荷或羧基保护基; R6或R7是H,C1-4烷基,(取代的)氨基或羟基; R8是H,C1-4烷基,氨基或羟基; Q是-CH-或= N-; X离开团体 m为0或1。
    • 8. 发明公开
    • 사이클로프로필 골격을 갖는 선택적 FXa 억제제
    • 具有环丙基结构的选择性FXA抑制剂
    • KR1020010081202A
    • 2001-08-29
    • KR1020000006354
    • 2000-02-11
    • 주식회사 엘지
    • 박태교장혜경이태희문광율이상구윤경희권오환강명균박두희이선화이승학박희동김동수박종우
    • C07D417/14
    • PURPOSE: A selective FXa inhibitor having a cyclopropyl structure is provided, which shows the improved selectivity to similar enzymes such as trypsin and thrombin. CONSTITUTION: Cyclopropyl derivatives are represented by formula (1), in which D is selected from amino, aminoiminomethyl and aminomethyl; A is phenyl, hydroxyphenyl, pyridine, thiophene, pyrimidine, naphthalene, quinoline, isoquinoline, benzofuran, benzothiophene and indole; R1 and R2 is individually H, F, Cl, Br, I, CN, CHO, CH2OR wherein R is hydrogen or linear, branched or ring lower alkyl having carbon number of 10 or less, CO2R, COR, CONR2, CH2NR2, CH2NR(C=O)R, CH2NR(SO2)R, CH2N(SO2R)2 and R; L is a linker and (CH2)m, wherein m is 0 or 1; P and Q are individually phenyl, pyridine, pyrol, furan, thiophene, oxazole, isooxazole, imidazole, 1,2-diazole, thiazole, isothiazole, pyridazine, pyrimidine, pyrazine, 1,2,3-triazole, 1,2,4-triazole, tetrazole and 1,3,5-triazine; X, Y and Z are individually H, F, Cl, Br, I, CN, CHO, OR, R, NR2, CO2R, COR, CONR2, NR(C=O)R, N((C=O)R)2, SO2NR2, SO2R, CF3, OCF3 and C(=NH)NH; and n is 0, 1, 2.
    • 目的:提供具有环丙基结构的选择性FXa抑制剂,其显示出对类似酶如胰蛋白酶和凝血酶的改善的选择性。 构成:环丙基衍生物由式(1)表示,其中D选自氨基,氨基亚氨基甲基和氨基甲基; A是苯基,羟基苯基,吡啶,噻吩,嘧啶,萘,喹啉,异喹啉,苯并呋喃,苯并噻吩和吲哚; R1和R2分别是H,F,Cl,Br,I,CN,CHO,CH2OR,其中R是氢或碳数为10以下的直链,支链或环状低级烷基,CO2R,COR,CONR2,CH2NR2,CH2NR( C = O)R,CH 2 NR(SO 2)R,CH 2 N(SO 2 R)2和R; L是连接基和(CH 2)m,其中m是0或1; P和Q分别为苯基,吡啶,吡喃,呋喃,噻吩,恶唑,异恶唑,咪唑,1,2-二唑,噻唑,异噻唑,哒嗪,嘧啶,吡嗪,1,2,3-三唑,1,2,4 三唑,四唑和1,3,5-三嗪; X,Y和Z分别为H,F,Cl,Br,I,CN,CHO,OR,R,NR2,CO2R,COR,CONR2,NR(C = O)R,N((C = O) 2,SO2NR2,SO2R,CF3,OCF3和C(= NH)NH; 并且n为0,1,2。
    • 9. 发明授权
    • 신규 세팔로스포린계 항생제 및 이의 제조방법
    • 新西酞菁抗生素
    • KR100257129B1
    • 2000-05-15
    • KR1019930018319
    • 1993-09-11
    • 주식회사 엘지
    • 여재홍방찬식임종찬우영민양덕호김세호전재훈서미경김삼식이태희김용주오헌승
    • C07D501/36
    • C07D501/00Y02P20/55
    • PURPOSE: A novel cephalosporin antibiotic product comprising the cephalosporin compound and other acceptable salts is provided for accomplishing excellent antibiotic activity to wide ranges of pathogenic bacteria including gram negative bacilli producing beta-lactamase and improved pharmaco-dynamic property. CONSTITUTION: The cephalosporin antibiotic product useful as antibiotic agent to pathogenic bacteria and having high pharmacological dynamic property comprises the cephalosporin compound of formula I (wherein R1 is hydrogen or amino protecting group; R2 and R3 are same or different and each represent hydrogen or hydroxy protecting groups or together form cyclic diol protecting group; R4 and R5 are independently hydrogen or carboxyl protecting group; R6 and R7 are independently hydrogen, amino group or substituted amino, hydroxy or alkoxy group, C1-C4 alkyl group, carboxy or alkoxycarboxyl group or R6 and R7 can form C5-C7 rings together with carbon atoms bonded to them; and Q is CH- or =N=) and pharmaceutical acceptable and non-toxic salts, physiologically hydrolytic ester, hydrate and solvent and isomers thereof.
    • 目的:提供一种包含头孢菌素化合物和其他可接受的盐的新型头孢菌素抗生素产品,用于对广泛范围的致病菌(包括革兰氏阴性杆菌产生β-内酰胺酶)和改善的药物 - 动力学性能实现优异的抗生素活性。 构成:用作致病菌抗菌素并且具有高药理动力学性质的头孢菌素抗生素产品包括式I的头孢菌素化合物(其中R 1为氢或氨基保护基; R 2和R 3相同或不同,各自表示氢或羟基保护基 基团或一起形成环状二醇保护基; R4和R5独立地是氢或羧基保护基; R6和R7独立地是氢,氨基或取代的氨基,羟基或烷氧基,C1-C4烷基,羧基或烷氧基羧基或R6 并且R7可以与其键合的碳原子一起形成C5-C7环; Q是CH-或= N =)和药学上可接受的和无毒的盐,生理水解酯,水合物和溶剂及其异构体。